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Abstract: Ratiometric approaches to quantifying molecular concentrations
have been used for decades in microscopy, but have rarely been exploited in
vivo until recently. One dual-tracer approach can utilize an untargeted
reference tracer to account for non-specific uptake of a receptor-targeted
tracer, and ultimately estimate receptor binding potential quantitatively.
However, interpretation of the relative dynamic distribution kinetics is
confounded by differences in local tissue absorption at the wavelengths
used for each tracer. This study simulated the influence of absorption on
fluorescence emission intensity and depth sensitivity at typical near-infrared
fluorophore wavelength bands near 700 and 800 nm in mouse skin in order
to correct for these tissue optical differences in signal detection. Changes in
blood volume [1-3%] and hemoglobin oxygen saturation [0-100%] were
demonstrated to introduce substantial distortions to receptor binding
estimates (error > 30%), whereas sampled depth was relatively insensitive
to wavelength (error < 6%). In response, a pixel-by-pixel normalization of
tracer inputs immediately post-injection was found to account for spatial
heterogeneities in local absorption properties. Application of the pixelbased normalization method to an in vivo imaging study demonstrated
significant improvement, as compared with a reference tissue normalization
approach.
©2014 Optical Society of America
OCIS codes: (170.3660) Light propagation in tissues; (170.3880) Medical and biological
imaging; (170.4580) Optical diagnostics for medicine.

References and links
1.
2.
3.
4.
5.

6.
7.

8.

R. Weissleder and M. J. Pittet, “Imaging in the era of molecular oncology,” Nature 452(7187), 580–589 (2008).
R. K. Jain, “Vascular and interstitial barriers to delivery of therapeutic agents in tumors,” Cancer Metastasis Rev.
9(3), 253–266 (1990).
H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, “Tumor vascular permeability and the EPR effect in
macromolecular therapeutics: a review,” J. Control. Release 65(1-2), 271–284 (2000).
J. W. Lichtman and J. A. Conchello, “Fluorescence microscopy,” Nat. Methods 2(12), 910–919 (2005).
R. B. Innis, V. J. Cunningham, J. Delforge, M. Fujita, A. Gjedde, R. N. Gunn, J. Holden, S. Houle, S. C. Huang,
M. Ichise, H. Iida, H. Ito, Y. Kimura, R. A. Koeppe, G. M. Knudsen, J. Knuuti, A. A. Lammertsma, M. Laruelle,
J. Logan, R. P. Maguire, M. A. Mintun, E. D. Morris, R. Parsey, J. C. Price, M. Slifstein, V. Sossi, T. Suhara, J.
R. Votaw, D. F. Wong, and R. E. Carson, “Consensus nomenclature for in vivo imaging of reversibly binding
radioligands,” J. Cereb. Blood Flow Metab. 27(9), 1533–1539 (2007).
B. W. Pogue, K. S. Samkoe, S. Hextrum, J. A. O’Hara, M. Jermyn, S. Srinivasan, and T. Hasan, “Imaging
targeted-agent binding in vivo with two probes,” J. Biomed. Opt. 15(3), 030513 (2010).
M. Ichise, J. S. Liow, J. Q. Lu, A. Takano, K. Model, H. Toyama, T. Suhara, K. Suzuki, R. B. Innis, and R. E.
Carson, “Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission
tomography studies of the serotonin transporter in human brain,” J. Cereb. Blood Flow Metab. 23(9), 1096–1112
(2003).
A. A. Lammertsma and S. P. Hume, “Simplified reference tissue model for PET receptor studies,” Neuroimage
4(3), 153–158 (1996).

#214089 - $15.00 USD Received 16 Jun 2014; revised 21 Aug 2014; accepted 23 Aug 2014; published 29 Aug 2014
(C) 2014 OSA

1 October 2014 | Vol. 5, No. 10 | DOI:10.1364/BOE.5.003280 | BIOMEDICAL OPTICS EXPRESS 3280

9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.

K. M. Tichauer, K. S. Samkoe, K. J. Sexton, S. K. Hextrum, H. H. Yang, W. S. Klubben, J. R. Gunn, T. Hasan,
and B. W. Pogue, “In Vivo Quantification of Tumor Receptor Binding Potential with Dual-Reporter Molecular
Imaging,” Mol. Imaging Biol. 14(5), 584–592 (2012).
K. M. Tichauer, M. Diop, J. T. Elliott, K. S. Samkoe, T. Hasan, K. St. Lawrence, and B. W. Pogue, “Accounting
for pharmacokinetic differences in dual-tracer receptor density imaging,” Phys. Med. Biol. 59(10), 2341–2351
(2014).
A. Soubret, J. Ripoll, and V. Ntziachristos, “Accuracy of fluorescent tomography in the presence of
heterogeneities: study of the normalized Born ratio,” IEEE Trans. Med. Imaging 24(10), 1377–1386 (2005).
A. K. Glaser, S. C. Kanick, R. Zhang, P. Arce, and B. W. Pogue, “A GAMOS plug-in for GEANT4 based Monte
Carlo simulation of radiation-induced light transport in biological media,” Biomed. Opt. Express 4(5), 741–759
(2013).
I. V. Meglinski and S. J. Matcher, “Quantitative assessment of skin layers absorption and skin reflectance spectra
simulation in the visible and near-infrared spectral regions,” Physiol. Meas. 23(4), 741–753 (2002).
S. L. Jacques, “Optical properties of biological tissues: a review,” Phys. Med. Biol. 58(11), R37–R61 (2013).
S. Gioux, H. S. Choi, and J. V. Frangioni, “Image-Guided Surgery Using Invisible Near-Infrared Light:
Fundamentals of Clinical Translation,” Mol. Imaging 9(5), 237–255 (2010).
A. A. Lammertsma, C. J. Bench, S. P. Hume, S. Osman, K. Gunn, D. J. Brooks, and R. S. Frackowiak,
“Comparison of methods for analysis of clinical [11C]raclopride studies,” J. Cereb. Blood Flow Metab. 16(1),
42–52 (1996).
S. S. Kety, “The theory and applications of the exchange of inert gas at the lungs and tissues,” Pharmacol. Rev.
3(1), 1–41 (1951).
Q. G. de Lussanet, S. Langereis, R. G. Beets-Tan, M. H. van Genderen, A. W. Griffioen, J. M. van Engelshoven,
and W. H. Backes, “Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of
dendritic contrast agents in tumor angiogenesis in mice,” Radiology 235(1), 65–72 (2005).
M. Zhou, S. Felder, M. Rubinstein, D. R. Hurwitz, A. Ullrich, I. Lax, and J. Schlessinger, “Real-time
measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the
dimerization model for receptor activation,” Biochemistry 32(32), 8193–8198 (1993).
K. S. Samkoe, K. Sexton, K. M. Tichauer, S. K. Hextrum, O. Pardesi, S. C. Davis, J. A. O’Hara, P. J. Hoopes, T.
Hasan, and B. W. Pogue, “High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in
AsPC-1 Tumors as Compared to Normal Pancreas,” Mol. Imaging Biol. 14(4), 472–479 (2012).
N. Hamzei, K. S. Samkoe, J. T. Elliott, R. W. Holt, J. R. Gunn, T. Y. Lee, T. Hasan, and B. W. Pogue,
“Comparison of kinetic models for dual-tracer receptor concentration imaging in tumors,” Austin J. Biomed.
Eng. 1, 9 (2014).
S. C. Kanick, D. J. Robinson, H. J. Sterenborg, and A. Amelink, “Monte Carlo analysis of single fiber
reflectance spectroscopy: photon path length and sampling depth,” Phys. Med. Biol. 54(22), 6991–7008 (2009).
K. Shirakawa, H. Kobayashi, J. Sobajima, D. Hashimoto, A. Shimizu, and H. Wakasugi, “Inflammatory breast
cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model,” Breast
Cancer Res. 5(3), 136–139 (2003).
C. Yang, V. W. Hou, E. J. Girard, L. Y. Nelson, and E. J. Seibel, “Target-to-background enhancement in
multispectral endoscopy with background autofluorescence mitigation for quantitative molecular imaging,” J.
Biomed. Opt. 19(7), 076014 (2014).
A. Kim, M. Khurana, Y. Moriyama, and B. C. Wilson, “Quantification of in vivo fluorescence decoupled from
the effects of tissue optical properties using fiber-optic spectroscopy measurements,” J. Biomed. Opt. 15(6),
067006 (2010).

1. Introduction
Approaches to quantitate the concentration of available molecular receptors in tissues of
interest in vivo have the potential to guide the development of targeted cancer therapeutics
[1]. Conventional molecular imaging can be complicated by multiple factors that can
influence extravasation, retention, and clearance of a targeted imaging agent within a tissue –
including perfusion volume, vascular permeability, lymphatic flow, receptor-binding, and
non-specific binding [2, 3] – making it intractable to quantify receptor binding or
concentration. A variety of ratiometric imaging methods (such as ratioing fluorescence at two
wavelengths: one sensitive to binding and one not) have been used extensively in
fluorescence assays and microscopy to provide more quantitative information about targeted
molecular expression [4]; however, they have been explored sparingly for in vivo studies
owing to tissue optical property differences at different wavelengths of light, which can be
difficult to account for. Recently, our group has reported on a dual-tracer approach to quantify
binding potential [BP: a metric that is equivalent to the affinity of the tracer to the target,
multiplied by the receptor concentration [5]]. The approach involves the simultaneous
administration and imaging of ‘targeted’ and ‘untargeted’ compounds [6]. Figure 1 presents
the detailed mathematics of the kinetics governing BP, using a linearized version [7] of
Lammertsma and Hume’s simplified reference tissue model [8], as applied to dual-tracer
#214089 - $15.00 USD Received 16 Jun 2014; revised 21 Aug 2014; accepted 23 Aug 2014; published 29 Aug 2014
(C) 2014 OSA

1 October 2014 | Vol. 5, No. 10 | DOI:10.1364/BOE.5.003280 | BIOMEDICAL OPTICS EXPRESS 3281

kinetics [9]. Note that the reference tissue models require tracer-receptor binding be less than
10% of saturation (for first order rate constants), that the bound and free states of the targeted
tracer are in rapid equilibrium, and that the ratio of K1/k2 (rate constants of extravasation and
tissue efflux, respectively: Fig. 1) be equivalent between target and reference curves [8]. For
application of these models to the dual-tracer methodology, the arterial input functions of the
two tracers also need to be equivalent [9], or any difference needs to be accounted for [10].
The models developed in the cited articles assume the targeted and reference signals are of
equivalent scale. For simple planar fluorescent imaging applications of this dual-tracer
approach, optical property differences at the wavelengths of fluorescence excitation and
detection of the two tracers must be accounted for (represented as ηT and ηU for the targeted
and untargeted tracers, respectively). In this study, the effects of blood volume and
oxygenation on optical property differences between two common near-infrared fluorescent
imaging bands are investigated, and two potential methods of correcting for these optical
property differences are evaluated: a reference tissue-based approach and a pixel-based
approach.
Normalization of the fluorescence emission intensities from the two tracers (represented
by the ratio of ηT / ηU ) accounts for variations in excitation intensities (φ ) , detector spectral
sensitivity

(K ) ,

tracer quantum yield ( Q ) , and attenuation as a function of background

optical properties f ( μt ) , some of which can vary spatially in

( x, y ) .

Therefore, for

fluorescence imaging of each tracer i ∈ [T , U ] , which designates targeted and untargeted,
respectively, the product of these factors yields ηi ( x, y ) = φi ( x, y ) K i ( x, y )Qi f ( μt ,i ( x, y )) .

While device specific quantities (i.e. φi , K i ) can be accounted for by accurate system
calibration, the role of optical properties may persist. The origin of μt ,i differences for the
targeted and untargeted tracers are attributable to excitation and emission pairings that are
located at different wavelengths. It is known that the local absorption coefficient [ μ a ( x, y )] at
a pixel in a wide field image is strongly dependent on the local hemodynamic parameters (e.g.
blood volume, hemoglobin saturation) and that variations in these parameters can alter the
attenuation of light remitted by each tracer differently; i.e. observed changes in fluorescence
may be attributable to variations in tracer concentrations or absorption coefficient.
Additionally, tracer-specific background μa values may result in different volumes or depths
of sensitivity for the collected fluorescence of each tracer, and such a depth mismatch would
violate an assumption that both tracers have been sampled from the same tissue volume in
vivo. Regional differences in μ a can be mitigated using images of the excitation fields
sampled by custom designed imaging setups to implement the Born normalization [11];
however, many commercially available small animal imaging systems that are optimized to
sample dual fluorescent targets do not explicitly sample the excitation field.
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Fig. 1. In vivo dual-tracer compartment model for cell-surface receptors. ROIT(t) and ROIU(t)
represent the measured uptake curves of the targeted and untargeted tracers, respectively, in
any region of interest, as a function of time, t; ηT and ηU are the imaging system detection
efficiencies for the targeted and untargeted tracers (see text for details); K1 and k2 are the rates
of exchange of the tracers from the blood concentration (Cp) to the interstitial space (Cf,2 for
the targeted tracer and Cf,1 for the untargeted tracer) and back, respectively; and k3 and k4 are
the rates of association and dissociation of the targeted tracer to its receptor in a bound state
(Cb), respectively. The fraction plasma volume in the tissue is represented by vp. The red
circled fraction in the black bordered equation is the parameter attained by the pixel-by-pixel
or reference tissue normalization approaches explored in this study. The BP, underlined in red,
is known as the “binding potential” and is the key parameter of interest: it is equivalent to k3/k4
and proportional to the receptor concentration by the tracer affinity.

This study considers two methods to normalize measured fluorescence images; Fig. 2
shows the use of these two methods on representative in vivo measurements on a mouse
model. The first method was the reference tissue approach, which was based on the
assumption that the uptake of the targeted and untargeted tracers should be the same in a
tissue devoid of receptor; any discrepancy in tracer-specific fluorescence remission is
measured by dividing the average uptake of the targeted tracer in the reference tissue by the
average uptake of the untargeted tracer. All untargeted tracer uptake images are then
corrected by scaling by this one normalization factor (Fig. 2(e)). The second approach was a
pixel-based normalization, wherein the uptake of the targeted and untargeted tracers is
assumed to be equivalent within the first 2 min after tracer injection in all tissues. Pixel-bypixel based normalization is then carried out by taking the dot-quotient of the targeted uptake
image and the untargeted uptake image at 2 min and then dot-multiplying all images by this
normalization factor map (Fig. 2(d)).
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This study utilizes Monte Carlo simulations of planar fluorescence imaging of two
targeted tracers to characterize the influence of physiologically-relevant optical property
variations on estimates of binding potential. Simulations are used to characterize the
sensitivity of sampled intensity and the depth of fluorescence origin for a pair of widely used
tracers that absorb in the 700 nm and 800 nm, respectively. Two methods for correcting
fluorescence used to estimate binding potential for distortions due to optical properties are
then used to analyze spatially resolved simulated data for validation, and then applied to
measurements made in mice in vivo to show the impact on estimated biological binding
potential.

Fig. 2. A gray-scale white light image of an exposed subcutaneous xenograph glioma tumor
grown on the left flank of an athymic mouse is depicted in (a). Targeted and untargeted tracer
uptakes at 2 min after tracer injection are presented in (b) and (c), respectively. The pixelbased normalization approach, wherein all untargeted tracer images are scaled by a
normalization factor map that is determined by dividing, pixel-by-pixel, the uptake images of
the targeted and untargeted tracers at 2-min post-injection, is depicted in (d). The reference
tissue-based normalization approach, wherein all untargeted tracer images are scaled by a
single normalization factor determined by the ratio of the uptakes of the targeted and
untargeted tracers in a region devoid of receptor is depicted in (e).

2. Methods

Monte Carlo simulations of fluorescence imaging of binding potential
A Monte Carlo model was used to simulate the planar fluorescence imaging of dual tracers in
mouse skin using previously validated code [12]. The model assumes that two tracers are
localized within a cylindrical inclusion (radius = 2 mm, height = 2 mm), akin to assessment of
molecular expression in either a subsurface tumor or lymph node. The inclusion was oriented
with the top face normal to the air/medium boundary of a larger surrounding phantom (x,ydimensions of 20 mm, z-dimension of 20 mm) and placed at selected subsurface depths
[0.25,0.5,1.0] mm. Figure 3(a) shows a schematic of the simulated measurement geometry.
The simulated source emitted wide-field illumination normal to the x-y phantom interface.
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The detector was approximated as a lens focused on the surface of the phantom and collected
all photons that remitted from the imaged surface. The optical properties of the sampled
medium and inclusion were matched, with the μ a constructed by specifying a basis set of
chromophores that included oxygenated and deoxygenated hemoglobin and a background
absorption contribution [13], with spectral profiles of background absorption shown in Fig.
3(b). Simulations were performed with permutations of blood volume fractions (BVF)s of [1–
3]% and hemoglobin saturations (Sat) of [0, 50, 100]%. The background reduced scattering
−1.2
coefficient ( μ s′ ) was specified as μ s′ = ( λ / 800nm ) , expressed in units of  mm −1  , with a
spectrally constant anisotropy = 0.8 and the index of refraction of the medium set to 1.38.
These properties approximated those commonly found in skin [14]. These simulations
considered tracers with excitation and emission properties selected to mimic IRDye-700DX
(IR700) and IRDye-800CW (IR800) dyes (LI-COR Biosciences, Lincoln, NE), with the
absorption and normalized emission spectra for both shown in Fig. 3(c); these dyes are at a
common wavelength of fluorophore emission in the near-infrared range [15]. Simulated
measurements excited IR700 and IR800 at 685 and 785 nm, respectively, and collected
spectrally-resolved fluorescence photons that remitted across the imaged phantom surface.
For each measured phantom, the total integrated fluorescence intensity for each tracer was
summed across the imaged surface and normalized to the mean of all simulations. A postprocessing algorithm estimated fluorescence in response to a time-dependent change in tracer
concentration by scaling collected photons for each tracer by the concentration as specified in
Fig. 3(d). Specifically, the targeted tracer uptake curve was simulated using the analytical
solution to the two-tissue compartment model shown on the right hand side of Fig. 1 [16].
The untargeted tracer was simulated using the analytical solution to the one-tissue
compartment model shown on the left hand side of Fig. 1 [17]. Values of K1 and k2 used for
both the targeted and untargeted tracer curve simulations were chosen based on values
measured for a 3.0-kDa imaging agent to match the size of the targeted tracer employed in the
animal experiments (~7 kDa): the values were K1 = 0.013 min−1 and k2 = 0.13 min−1 [18]. The
disassociation binding rate constant k4 is equivalent to koff in enzyme kinetic nomenclature
and was measured by Zhou et al. to be approximately 0.1 min−1 for EGF bound to EGFR [19]
- native EGF was the targeting moiety used in the animal experiments in this study. Then with
binding potentials (k3/ k4) roughly equivalent to 2 for a typical EGFR overexpressing tumor
line (U251: see Animal experiments), k3 was by association assumed to be equal to 0.2 min−1.
A typical arterial input function was taken from a prior study looking at fluorescence in blood
samples using the same tracers employed in the animal experiments in the current study [20].
Targeted tracer uptake curves were simulated based on the equation in Fig. 1 using the
untargeted tracer as input and assuming the same k2 and specifying the BP. Resulting
fluorescence vs. time data were analyzed using a linearized solution to the Equation set
 . Simulations also
shown in Fig. 1, as in [7, 21], returning estimates of binding potential, BP
returned the depth of origin for collected fluorescence photons, which were used to generate
depth sensitivity histograms for each tracer and a weighted sampled depth as in [22]. Each
simulation initialized 108 excitation photons, with emission sampled at 10 discrete
wavelengths within the tracer specific emission waveband. In all, fluorescence spectra for 2
tracers were measured in phantoms with 9 background μ a values with fluorescence
inclusions located at 3 depths, resulting in 54 simulated spectra, each of which were used to
estimate a fluorescence intensity at 60 time points.
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Fig. 3. a) Schematic of simulated measurement geometry. b) Absorption spectra for 2% blood
volume at selected saturations and background absorption. c) Absorption (solid) and emission
(dashed) spectra for dual tracers (i.e. IR700 and IR800). Vertical dashed lines in both panels
represent integrated waveband for fluorescence intensity. d) Time-dependent concentrations of
targeted and untargeted tracers for binding potential = 1.7.

Additional simulations were performed to mimic spatially-resolved fluorescence imaging
of a medium that contains absorbing inclusions. These simulations considered a semi-infinite
medium, with a 30x30 mm field of view with background absorption specified by BVF = 2%,
Sat = 70%. The medium contained two absorbing inclusions with a radius of 5 mm. The first
inclusion was centered at (x,y) coordinates of (19.25,19.25) mm and contained [BVF = 25%,
Sat = 50%], while the second was centered at (11.25,11.25) mm and contained [BVF = 100%,
Sat = 0%]. A fluorescence inclusion with radius of 10 mm centered at the (15,15) mm with the
top face positioned at the air/medium interface was placed in the medium. An x-y view of the
geometry with inclusions is shown in Fig. 5(a). Within the volume of the phantom
surrounding the inclusion, the concentration of both IR700 and IR800 were specified by the
‘untargeted’ curve in Fig. 3(d). Within the fluorescence inclusion the concentration dynamics
of IR800 were specified by the ‘targeted’ curve in Fig. 3(d). Simulations tracked all
fluorescent emission photons that transmitted from the imaged phantom surface and for each
photon returned the wavelength, the location of origin from within the phantom, and the
location of remission from the phantom surface. Fluorescence images were produced by
discretizing the location of remission on the surface of the medium into a 2-D (x,y) grid with
bin dimensions of 0.5 mm and integrating the collected spectra over the tracer-specific
wavebands. A post-processing algorithm estimated time-dependent emission maps by
weighting the photons collected at each pixel by the concentration of the tracer at the location
of origin; these data were used to simulate fluorescence maps at 1 min time intervals for 60
min. Binding potential maps were calculated at each pixel in the image using a linearized
simplified reference tissue approach (Fig. 1) [7, 21], using both reference- and pixel-based
normalization procedures to determine the normalization factor, ηT/ηU.
Experimental measurements of binding potential in a mouse model
Three 6-week-old male severe combined immunodeficient (SCID) mice were implanted with
106 U251 human glioma cells (from Dr. Israel at Dartmouth College) subcutaneously in the
left flank, explained in more detail in a previous study [22]. Once the tumors grew to a
diameter of approximately 5 mm, the mice were anesthetized with an intra-peritoneal
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injection of ketamine-xylazine (100 mg/kg:10 mg/kg) and a small section of skin was excised
to expose the tumor. The mice were then affixed, tumor-side-down, to a standard glass
microscopy slide and placed in a two-fluorescence-wavelength, Odyssey imaging system (LICOR Biosciences). The mice were injected intravenously in the tail vein with 1 nanomole of
both IRDye-800CW-EGF [an epidermal growth factor (EGFR) targeted tracer (LI-COR
Biosciences)] and IRDye-700DX (LI-COR Biosciences). Fluorescence from each tracer was
imaged repeatedly in the tumor and surrounding tissue at 2-min intervals for up to 60 min.
Location of the tumor was clear on pre-injection autofluorescence images taken with the
odyssey scanner at 700 nm [20]. We used this image to select tumor and reference regions.
Binding potential maps were calculated using a linearized simplified reference tissue
approach (Fig. 1) [7, 21], using both reference- and pixel-based normalization procedures to
determine ηT/ηU.
3. Results

Figure 4(a) shows a representative fluorescence remission spectrum for both tracers for
different Sat values [0, 50, 100] % at constant BVF = 2%. These spectra show that differences
in physiological parameters introduce differences in the remission intensity collected for each
tracer; these differences are clearly visible for IR700, but not for IR800. The equation set in
Fig. 1 was applied to simulated fluorescence emission profiles, and residuals between known

 ) values of BP were given as, 100% BP −  BP ; these errors
(  BP ) and estimated ( BP
 BP

 plotted vs.
represent absorption-dependent variations in BP . Figure 4(b) shows error in BP
Sat for different BVF; these data were calculated for  BP = 1.7. The data show that
estimates of binding potential are more sensitive to variations in Sat (with a maximum error
of 26%) than in BVF (11%). This observation can be explained by considering the different
influence these parameters have on the μ a spectrum: changes in Sat introduce a spectrally
dependent change to μa , while changes in BVF introduce a linear shift across the full μa
spectrum. Absorption-based error in BP was also assessed for different inclusion depths and
 BP values; the summary of the combined variations is shown in Fig. 4(c). Binding
potential error increased with inclusion depth, which is expected as attenuation increases with
path length. BP error also increased for smaller  BP values, which can be understood by
considering that as the binding-dependent difference in fluorescence emission decreases,
.
absorption-based distortions have a more substantial influence on BP
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Fig. 4. a) IR700 emission spectra for various Sat (inset for IR800); b) Error in BP vs. Sat; c)
Maximum error in BP vs. expected BP for various inclusion depths; d) Depth sensitivity for
both tracers for BVF = 2% and Sat = 100%; e) Tracer depth mismatch vs. Sat; f) Mean
sampling depth vs. inclusion depth. In b and e markers indicate BVF and colors indicate Sat.

Figure 4(d) shows representative depth sensitivity profiles for fluorescence intensity
collected for both tracers measured for simulated the physiological case of Sat = 100%, BVF
= 2%; these profiles displayed near matching sampling depth for both tracers. Figure 4(e)
shows the difference between the depths of origin for both tracers (expressed as a %) vs. Sat
for selected BVF values. Here, the depths are exceptionally well matched, with error of <6%
for all cases. In Fig. 3(f) the sampled vs. inclusion depth shows a simple linear increase, with
no observable spread among tracer data points for all μ a combinations. These data validate a
key assumption that both tracers are sampled within matching tissue volumes.
Figure 5 shows the application of the normalization methods to spatially-resolved
simulated measurements of a turbid medium containing absorbing inclusions. Figure 5(a)
shows the phantom geometry, with two absorbing and one fluorescence inclusion. Figure 5(b)
and 5(c) show raw emission intensities for the fluorescence collected for both IR700 and
IR800. Here the fluorescence emission results from near-uniform distribution of both tracers
throughout the model geometry, but these images show substantial distortion due to
background absorption by both inclusions. Taking a ratio of the images in Fig. 5(b) and 5(c)
yielded a pixel-based calibration map of ηT / ηU , which is shown in Fig. 5(d). Reference
tracer estimation of ηT / ηU was by selecting a 1 mm2 region centered at x = 5, y = 25 mm, a
location away from the heterogeneities. Figure 5(e) and 5(f) show fluorescence images for
both IR700 and IR800 sampled at 60 min; these data show similar a distribution pattern for
the untargeted tracer, but a substantial increase in fluorescence of the targeted tracer (IR800)
is observed in the center of the image over the fluorescence inclusion. Figure 5(g) and 5(h)
show images of spatially-resolved maps of binding potential estimates for the non-uniform
fluorescence distributions as returned by the reference tissue and pixel-based normalization
methods, respectively. The true binding potential value in each map is  BP = 1.7 . The image
obtained from the reference tracer method shows clear distortions in the estimates of BP both
in and around the fluorescence inclusion for the reference model (with the mean error of
< 35 ± 20% ), while the pixel-based model recovers the embedded fluorescence inclusion
with clear demarcation and substantially reduced distortions (with mean error of < 6 ± 3% ).
These results validate the use of pixel-based normalization procedure to account for spatiallyresolved differences in background absorption.

#214089 - $15.00 USD Received 16 Jun 2014; revised 21 Aug 2014; accepted 23 Aug 2014; published 29 Aug 2014
(C) 2014 OSA

1 October 2014 | Vol. 5, No. 10 | DOI:10.1364/BOE.5.003280 | BIOMEDICAL OPTICS EXPRESS 3288

Fig. 5. a) Model geometry of a turbid medium containing two absorption inclusions (1) BVF =
25%, Sat = 50% and (2) BVF = 100%, Sat = 0%. b) and c) Show simulated fluorescence
images with of IR700 and IR800 at 2 min, respectively. d) Shows the pixel-based
normalization map. e) and f) Show simulated images of both tracers at 60 min. g) and h) Show
binding potential maps for images in the presence of the absorption inclusions as estimated by
both the reference tracer method and pixel-by-pixel normalization method, respectively.

Figure 6 shows the application of these approaches to estimating binding potential in a
murine subcutaneous tumor model. Normalization of the images to determine ηT / ηU was
performed using images obtained at early time points (i.e. 2 min following simulations tracer
injections), a time point when both tracers are expected to share matching perfusion-based
kinetics. Figure 6 columns 1 and 2 show EGFR receptor concentration (e.g. BP) estimated by
the reference- and pixel-based normalization procedures, respectively. The changes in
normalization procedure yielded a different bulk BP estimate of EGFR concentration in the
tumor (yielding a 38 ± 5% decrease in BP). Also interesting is that the estimated maps show
differences in the spatial distribution of BP, differences that are not recovered by a linear
scaling operator. Instead these spatial differences are presumably attributable to differences in
the local μa (between pixels), which introduced a spatial distortion factor in the reference
tissue map; this distortion can be seen in the normalization factor map for Mouse 1 in Fig.
2(d) and is removed through self-normalization using the pixel-based method. Inspection of
the dynamic fluorescence vs. time profiles in Fig. 1(e) shows that the reference-based
approach yields appropriately matched profiles for both tracers in normal tissue at all time
points. However, the data in Fig. 6 (far right) show that the pixel-based approach yields an
improved match for both tracers at early times. While these in vivo data do not provide
definitive confirmation of the local tracer concentrations, this approach assumes that tracer
distribution at these time points is dominated by plasma-based kinetics, and as a result, the
distribution for both tracers is similar. These results suggest the pixel-based normalization
procedure removes the influence of absorption-based differences in BP calculations.
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Fig. 6. Binding potential maps calculated using the reference tissue-based normalization (first
column of images) and the pixel-based normalization approach (second column of images) are
presented for 3 athymic mice with subcutaneous xenograph glioma tumors. The binding
potential (BP) measured in each case within the tumor is displayed on the figure. For
reference, the white-light image for Mouse 1 is depicted in Fig. 1(a). On the far right, the
average targeted tracer uptake (red curve) in the tumor is presented along with the untargeted
tracer uptake after normalization by the reference tissue-based approach (dotted green curve),
and by the pixel-based approach (solid green curve).

4. Discussion

This study investigates fluorescence normalization approaches necessary to quantitatively
image receptor binding potential in vivo using a dual tracer method. The approaches employ
the administration of two fluorescent tracers, one ‘targeted’ to a specific receptor (e.g. EGFR)
and the other ‘untargeted’. Previous work has shown that interpretation of fluorescence
images of both tracers could be used to quantitate the binding potential, which is a surrogatemetric for the concentration of a receptor in tissue in vivo [5]. The dual-tracer approach
involves the optical sampling of two tracers that absorb and emit at different wavelengths;
therefore, variability in biological chromophores (e.g. oxy- and deoxy-hemoglobin) can
introduce differential distortions in the remission intensity of the two tracers. This study
utilized simulations to mimic wide field fluorescence imaging of two dyes commonly used in
the NIR (i.e. IRDye-700DX and IRDye-800CW) over a wide range of vascular physiological
parameters, including blood volume fractions in the range of [1–3]% and hemoglobin
saturations in the range [0-100%]%. Substantial distortion in the absolute estimates of binding
potential (BP) in response to changes in background absorption was observed (with >30%
error observed in BP); however the fluorescence sampled for both tracers originated in similar
depths over the parameter space. These results suggested that proper normalization of
fluorescence images is required to correct for distortions introduced by spatial-variations in
absorption. These results motivated the comparison of two basis approaches to obtain the
normalization factor ηT / ηU : (1) determination within a reference location in ‘normal’ tissue
(devoid of targeted receptor), which is then applied to all pixels in the image field, or (2) a
pixel-by-pixel basis. Simulation of spatially-resolved fluorescence imaging in the presence of
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strong absorption inclusions showed the influence that differences in vascular density, or even
extreme situations such as blood pooling, known to occur in tumors [23], which have
substantial influence on fluorescence remission can be corrected for using a pixel-based
normalization approach. Prospective application of these two methods to in vivo data showed
substantial differences between the references tissue model and pixel-by-pixel normalization
estimates of receptor distribution within human xenograft tumors grown in mice.
Ideally, the pixel-by-pixel normalization should be carried out on data points collected as
soon after the injection as possible, when the arrivals of the targeted and untargeted tracers to
the tissue are predominantly based on delivery (blood flow and vascular leakage, i.e., K1
based). At these early time-points, any discrepancy between measured targeted and
untargeted tracer concentration should predominantly be associated with detection efficiency
differences and/or optical property differences for the different wavelengths at which the
tracers are detected. At later time-points, the delivery of the targeted tracer will become
increasingly dependent on binding to the targeted receptor, and will therefore begin to
separate (be retained in the tissue to a greater extant) from the untargeted tracer. Note: if there
is no receptor present in the tissue of interest, the targeted and untargeted tracers should
remain at equivalent levels.
Expanding on the curve simulations describe in the Monte Carlo Methods, an additional
set of targeted tracer uptake curves were created for binding potentials (BPs) of 0 to 5. For all
statistical analyses, 1% of peak signal noise (larger than the highest noise per pixel in the
animal experiments) was added to the data and analyses were repeated with random noise
addition for 100 iterations. The data was assumed to be collected at 1-min intervals beginning
at 1 min post-injection. The optimal time window for data normalization was explored by
normalizing the targeted tracer curves to the untargeted tracer untargeted tracer curves at 1
min, 1:2 min, 1:5 min, and 1:10 min post-injection, after the targeted tracer was randomly
scaled by a number between 0.5 and 2 to simulate variability in optical properties (Fig. 7). As
demonstrated, the optimal mean estimation of BP was achieved when the normalization was
carried out at the 1 min interval, with BP underestimates of just over 5%. However, the
variance in these estimates was substantial (approximately 15% of the mean), owing to poor
noise stability with averaging on one time-point. The best standard deviation of ~2% of the
mean was achieved for the 1:10 min normalization because of the preferable noise
characteristics of averaging over 10 measurements; however, this normalization window
extended well into the “binding window” (when binding accounts for a significant percentage
of targeted tracer uptake) resulting in a mean underestimation in BP of approximately 60%.
Qualitatively, the best tradeoff between accuracy and precision was observed for the 1:2 min
normalization with a mean error of approximately 10 ± 10%. This was the same window used
in the pixel-by-pixel normalization in all other studies in this work. It should be noted that
with higher temporal resolution and better signal-to-noise characteristics, BP estimates could
be improved by carrying out the normalizations at as earlier a time-point as possible.
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Fig. 7. Simulation study results to determine the optimal time-window in which to normalize
targeted and untargeted tracer uptake curves to correct for optical property and detection
efficiency mismatch between tracers. In (a), the various simulated targeted tracer uptake curves
based on binding potentials (BP) between 0 and 5 are presented over 60 min. In (b), the same
curves in (a) are re-plotted for just the first 10 min of uptake. The shaded regions demonstrate
the ranges over which the 1-min (blue), 2-min (red), 5-min (green), and 10-min (purple)
normalizations were carried out. The results of these normalizations and their affects on BP
estimation are presented in (c) in the form of a Bland-Altman.

The pixel-based normalization approach characterized in this study makes images of
receptor concentration insensitive to spatial-variations in background absorption without the
need for a light-transport model based correction, which is a focus of many groups and
typically requires multispectral imaging systems [14, 24, 25]. It should be noted that while the
proposed normalization method cannot account for dynamic variations in μ a that may occur
during tracer monitoring, the anticipated spatial variation in μa between different regions in
the sampled field of view is expected to dominate dynamic changes to μa that may occur
within a single pixel. While demonstrated in a specific application, this early time-point,
pixel-by-pixel normalization approach could allow ex vivo ratiometric microscopy approaches
to be translated to in vivo applications, allowing users to account for uneven-distribution of
the tracer excitation, detection sensitivity, and tissue attenuation of tracer signal, as long as
the imaging system has linear detection in both channels.
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